OrthoPediatrics reported record Q2 2026 revenue of $70.5 million, a 15% increase year-over-year, driven by strong growth in Trauma & Deformity products and international sales. The company improved adjusted EBITDA to $6.8 million and significantly reduced free cash flow usage by 78%. It also raised its full-year 2026 revenue guidance to $265-269 million, expecting 12-14% growth and breakeven free cash flow. This reflects confidence in its pediatric orthopedic market leadership and ongoing innovation.
The fourth Digital Assets & Tokenization Summit held in Singapore brought together global financial leaders, institutional investors, and tech innovators to discuss how AI, tokenization, and digital assets are transforming capital markets. Key discus...
A London-based novelist, using the pen name A. Nobody, has independently published a thriller titled "A Nobody: London Doesn't Believe in Superheroes." The story follows a masked hero who stops violent crimes in London anonymously, reflecting the aut...
In the past 24 hours, 80 of the 90 largest cryptocurrencies by market cap declined, with Pump.fun (PUMP) experiencing the steepest drop of 13.76% to $0.00436. Other notable losses included Zcash down 13.07% and Canton falling 12.75%. Meanwhile, only ...
Oil prices fell as a Singapore-registered ship was sunk in the strategic Strait of Hormuz, raising fears of prolonged Middle East conflict. The International Energy Agency warned that diesel supply constraints could persist into next year, while tens...
The NEAR/USDT trading pair on Binance spot fell 3.02% within one hour, dropping from $4.80 to $4.65. During this period, liquidations of NEAR positions across Binance, Bybit, and OKX totaled $170,000, with $130,000 in long positions and $40,000 in sh...
